

January 25<sup>th</sup>, 2018

For Immediate Release  
To Whom It May Concern

Mitsui & Co., Ltd.

Notice for share transfers and deconsolidation of MBK Healthcare Partners Ltd.

Mitsui & Co., Ltd. ("Mitsui", Head Office: Tokyo, President and CEO: Tatsuo Yasunaga) announced that , MBK Healthcare Partners Ltd. ("MBKHP"), a wholly owned subsidiary, has transferred its entire shares in IHH Healthcare Berhad ("IHH") to Mitsui, and that Mitsui plans to liquidate this subsidiary.

As a result of the share transfers, approximately ¥9.0 billion gains on the reversal of deferred tax liability on undistributed profits is expected to be recorded in Mitsui's full year consolidated financial results for the fiscal year ending March 2018. This profit is not included in the consolidated financial result revised forecasts announced by Mitsui on November 2<sup>nd</sup>, 2017.

1. Reason for the deconsolidation

The status of MBKHP has changed from a consolidated subsidiary to an unconsolidated subsidiary as a result of reduction in paid-in capital after investments held by MBKHP have been transferred to Mitsui, and Mitsui's plan to liquidate MBKHP. MBKHP was established for the purpose of managing its investments in IHH. The recent business environment has led to the aforementioned transfer of investments and the planned liquidation as part of Mitsui's cost-cutting and streamlining measures.

2. MBK Healthcare Partners Ltd.

Company Name	MBK Healthcare Partners Limited
Address	The United Kingdom
Representative	Takeshi Saito, Director
Established	5 <sup>th</sup> April 2011
Capital	1,239,000,000 SGD (Before transfer)

Business Operation	Management of investments in IHH
Shareholder	Mitsui & Co., Ltd. 100%
Relationship with Mitsui & Co., Ltd.	Capital relationship: Mitsui & Co., Ltd. has a 100% stake in MBKHP. Personnel Relationship: Mitsui & Co., Ltd. has directors in MBKHP. Business relationship: There is no business relationship to be stated.

3. Status of owned shares before and after capital reduction

Before	1,238,685,428 (Number of voting rights:1,238,685,428, Ownership:100%)
After	1 (Number of voting rights:1, Ownership:100%)

4. Dates

Capital reduction: January 25th, 2018

Liquidation: Resolution of liquidation will be scheduled on January 29th, 2018.

Registration of liquidation will be expected by the end of September, 2018.

5. IHH Healthcare Berhad

Company name	IHH Healthcare Berhad
Address	Malaysia
Representative	Dr. Tan See Leng, Managing Director and CEO
Business operation	Healthcare related business such as hospital management and medical institution management etc. in Asia, Central and Eastern Europe, the Middle East and the North Africa region
Shareholding structure (after transfer)	Mitsui & Co., Ltd. 18%, Others 82%

For inquiries on this matter, please contact:

Mitsui & Co., Ltd.  
Investor Relations Division  
Telephone: +81-3-3285-7910  
Facsimile: +81-3-3285-9821  
infoTKADZ@mitsui.com

Mitsui & Co., Ltd.  
Corporate Communications Division  
Telephone: +81-3-3285-6645  
Facsimile: +81-3-3285-9819

Notice:

This announcement contains forward-looking statements. These forward-looking statements are based on Mitsui's current assumptions, expectations and beliefs in light of the information currently possessed by it and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause Mitsui's actual results, financial position or cash flows to be materially different from any future results, financial position or cash flows expressed or implied by these forward-looking statements. These risks, uncertainties and other factors referred to above include, but are not limited to, those contained in Mitsui's latest Annual Securities Report and Quarterly Securities Report, and Mitsui undertakes no obligation to publicly update or revise any forward-looking statements.

This announcement is published in order to publicly announce specific facts stated above, and does not constitute a solicitation of investments or any similar act inside or outside of Japan, regarding the shares, bonds or other securities issued by us.

The information contained in this release is true and accurate at the time of publication; however, it may be subject to change without prior notice.